Profil
Arjan W.
Griffioen is the founder and Chief Scientific Officer of CimCure BV, which is founded in 2015.
Dr. Griffioen is also the founder of PepTx, Inc. Dr. Griffioen's former job was Chief Scientific Officer at SomantiX BV.
Postes actifs de Arjan W. Griffioen
| Sociétés | Poste | Début |
|---|---|---|
| PepTx, Inc. | Fondateur | 09/06/2011 |
CimCure BV
 CimCure BV Miscellaneous Commercial ServicesCommercial Services CimCure BV is a Dutch new generation company founded in 2015 as a spin-off of the VU University Medical Center. CimCure is based in Amsterdam, Netherlands. The company focuses on the design and development of a novel class of active cancer vaccines that target the tumor blood vessels common to most solid tumors. CimCure has discovered and patented multiple highly specific targets and a novel conjugate vaccine technology that can induce polyclonal antibody responses to targets specific to the tumor vasculature. The company aims to combine the proven efficacy of tumor angiogenesis inhibition with the advantages that a vaccine may provide. The company was founded in 2015 by Arjan W. Griffioen, and Diederik Engbersen has been the CEO of the company since 2020. | Fondateur | 01/01/2015 |
Anciens postes connus de Arjan W. Griffioen
| Sociétés | Poste | Fin |
|---|---|---|
SomantiX BV
 SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
SomantiX BV
SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Commercial Services |
| PepTx, Inc. | |
CimCure BV
CimCure BV Miscellaneous Commercial ServicesCommercial Services CimCure BV is a Dutch new generation company founded in 2015 as a spin-off of the VU University Medical Center. CimCure is based in Amsterdam, Netherlands. The company focuses on the design and development of a novel class of active cancer vaccines that target the tumor blood vessels common to most solid tumors. CimCure has discovered and patented multiple highly specific targets and a novel conjugate vaccine technology that can induce polyclonal antibody responses to targets specific to the tumor vasculature. The company aims to combine the proven efficacy of tumor angiogenesis inhibition with the advantages that a vaccine may provide. The company was founded in 2015 by Arjan W. Griffioen, and Diederik Engbersen has been the CEO of the company since 2020. | Commercial Services |
